MUSCLE AND BACK PAIN PLATINUM RELIEF TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
13-01-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
METHOCARBAMOL; IBUPROFEN
Beschikbaar vanaf:
VITA HEALTH PRODUCTS INC
ATC-code:
M03BA53
INN (Algemene Internationale Benaming):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dosering:
500MG; 200MG
farmaceutische vorm:
TABLET
Samenstelling:
METHOCARBAMOL 500MG; IBUPROFEN 200MG
Toedieningsweg:
ORAL
Eenheden in pakket:
18/40
Prescription-type:
OTC
Therapeutisch gebied:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0248961001; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2014-03-11
Productkenmerken
Page 1 of 41
PRODUCT MONOGRAPH
MUSCLE AND BACK PAIN PLATINUM RELIEF
Methocarbamol and Ibuprofen Caplets
500mg/200mg
Muscle Relaxant/Analgesic
VITA HEALTH PRODUCTS INC. Date of Preparation:
150 Beghin Avenue March 4, 2014
Winnipeg, MB
R2J 3W2 Date of Revision:
December 2, 2019
Control Number 231400
Page 2 of 41
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
...................................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................................3
CONTRAINDICATIONS
..............................................................................................................3
ADVERSE
REACTIONS..............................................................................................................11
DRUG
INTERACTIONS..............................................................................................................13
DOSAGE AND
ADMINISTRATION..........................................................................................16
OVERDOSAGE
...........................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................18
STORAGE AND
STABILITY......................................................................................................20
SPECIAL HANDLING INSTRUCTIONS
..................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................21
PART II: SCIENTIFIC
INFORMATION................................................................................22
PHARMACEUTICAL
INFORMATION......................................................................................22
CLINICAL
TRIALS..................................................
Lees het volledige document
